Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I trial of RB-571/RB-515 (REG3) for potential use as an antiplatelet therapy.

Trial Profile

A phase I trial of RB-571/RB-515 (REG3) for potential use as an antiplatelet therapy.

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RB 571/RB 515 (Primary)
  • Indications Diabetic complications; Thrombosis
  • Focus Adverse reactions

Most Recent Events

  • 07 Nov 2011 Planned initiation date changed to 31 Dec 2011, according to a Regado Biosciences media release.
  • 13 Aug 2010 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top